- Home
- REFI vs VNDA Comparison
REFI vs VNDA Comparison
Compare REFI & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | VNDA |
|---|---|---|
| Founded | 2021 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 474.0M |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | REFI | VNDA |
|---|---|---|
| Price | $11.23 | $7.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.90 |
| AVG Volume (30 Days) | 188.5K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 16.82% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | $48,857,628.00 | ★ $216,105,000.00 |
| Revenue This Year | $15.98 | $21.35 |
| Revenue Next Year | $1.33 | $37.40 |
| P/E Ratio | $6.65 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $10.74 | $3.81 |
| 52 Week High | $15.20 | $9.91 |
Technical Indicators
Market Signals| Indicator | REFI | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 34.96 | 48.89 |
| Support Level | N/A | $7.12 |
| Resistance Level | $12.59 | $8.29 |
| Average True Range (ATR) | 0.32 | 0.46 |
| MACD | -0.11 | -0.06 |
| Stochastic Oscillator | 25.00 | 34.45 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.